J. G. Paez, P. A. Jänne, and J. C. Lee, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, vol.304, pp.1497-500, 2004.

S. J. Rodig, M. Mino-kenudson, and S. Dacic, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin Cancer Res, vol.15, pp.5216-5239, 2009.

B. J. Solomon, T. Mok, and D. W. Kim, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, vol.371, pp.2167-77, 2014.

M. Von-laffert, P. Schirmacher, and A. Warth, ALK-Testung beim nicht-kleinzelligen Lungenkarzinom (NSCLC): immunhistochemie (IHC) und/oder Fluoreszenz-in-situ-Hybridisierung (FISH)?, Pneumologie, vol.70, pp.277-81, 2016.

N. B. Leighl, N. Rekhtman, and W. A. Biermann, Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline, J Clin Oncol, vol.32, pp.3673-3682, 2014.

M. W. Wynes, L. M. Sholl, and M. Dietel, An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators, J Thorac Oncol, vol.9, pp.631-639, 2014.

L. Shan, P. Jiang, and F. Xu, BIRC6-ALK, a Novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib, J Thorac Oncol, vol.10, pp.37-39, 2015.

V. Martin, B. Bernasconi, and E. Merlo, ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice, J Thorac Oncol, vol.10, pp.595-602, 2015.

N. Peled, G. Palmer, and F. R. Hirsch, Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinibsensitive ALK rearrangement in a patient with metastatic non-smallcell lung cancer, J Thorac Oncol, vol.7, pp.14-16, 2012.

A. J. Van-der-wekken, R. Pelgrim, and N. Hart, Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer, Clin Cancer Res, vol.23, pp.4251-4259, 2017.